Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > ACADEMIA
ACADEMIA
- 8.5% of Long-COVID Patients Still Seriously Affected after 6 Months: Survey
July 4, 2024
- Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
June 24, 2024
- MHLW-Funded Study Group Designing New Care Delivery Model for Alzheimer’s
June 14, 2024
- Leukemia Drug Slows ALS Progression in Japan Clinical Trial
June 13, 2024
- Akira Endo, Who Pioneered Discovery of Statins, Dies at 90
June 12, 2024
- Single-Injection Beyfortus Will Reduce Burdens on Parents and Children: Experts
June 10, 2024
- Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
May 14, 2024
- Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
May 8, 2024
- Lecanemab Combo Trial Launched in Japan for Familial Alzheimer’s
March 18, 2024
- Pediatric Specialist Pins Hope on Efficacy of Pfizer’s RSV Shot in Healthy Infants
March 12, 2024
- Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
March 8, 2024
- JSMO Panelists Urge Measures to Lure US Biotechs to Fight Drug Loss
February 27, 2024
- Pneumococcal Jabs Help Curb Pediatric Emergency Visits: Pediatrician
February 26, 2024
- KOL Highlights Need for Further RSV Epidemiological Research in Japan
February 15, 2024
- Drug Loss Is Intensifying for Rare Cancers amid Rise of Biotech Developers: JSMO Director
February 5, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- National Geriatrics Center to Kick Off Leqembi Treatment on Feb. 13
January 25, 2024
- NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
January 22, 2024
- Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
- Medical Interns Improperly Prescribe, Use GLP-1 Agent for Off-Label Purpose
December 18, 2023
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…